Patent application number | Description | Published |
20100015544 | TONER PROCESS - The present disclosure provides toners and processes for preparing toner particles possessing excellent charging characteristics. The process includes forming a dispersion including at least one organic and/or organometallic charge control agent, and then combining that dispersion with an emulsion suitable for use in forming toner particles. | 01-21-2010 |
20100143839 | TONER PROCESS - The present disclosure provides processes for increasing the shelf life and stability of resin emulsions suitable for use in forming toner particles. In embodiments, the pH of the resin emulsion is monitored, and a base is added as needed to maintain the pH of the emulsion at from about 6.5 to about 8. Maintaining the pH at from about 6.5 to about 8 prevents the degradation of the resin in the emulsion, including its molecular weight. | 06-10-2010 |
20100297546 | TONER COMPOSITIONS - Toner particles are provided which may, in embodiments, include a core and a shell. In embodiments, charge control agents may be co-emulsified with a resin utilized to form a shell. The shell may prevent a crystalline resin in the core from migrating to the toner surface. Inclusion of the charge control agent in the shell itself may provide the resulting toner particles with desirable charge characteristics and sensitivity to relative humidity. | 11-25-2010 |
20140045116 | EMULSION AGGREGATION TONER PROCESS COMPRISING DIRECT ADDITION OF SURFACE-TREATED PIGMENT - A method of making a toner that includes adding pigments into an emulsion aggregation toner without first preparing a pigment dispersion. The method eliminates the pigment dispersion step in the manufacture of emulsion aggregation toilers by surface-treating pigments. Dry surface-treated pigments can be directly incorporated into the toner prior to aggregation in the aggregation coalescence process without the need to first prepare aqueous pigment dispersions. | 02-13-2014 |
20140199625 | Preparing Amorphous Polyester Resin Emulsions - A process for making a latex emulsion including contacting at least one amorphous polyester resin with at least two organic solvents to form a resin mixture, adding a neutralizing agent, and deionized water to the resin mixture, removing the solvent from the formed latex, and separating the solvent from water. Further, the process is carried out above the resin Tg for making the latex, which drives the latex particle size under 100 nm, where toners made from the latex show improved charging performance. | 07-17-2014 |
Patent application number | Description | Published |
20080275684 | TREATMENT PROTOCOL GENERATION FOR DISEASES RELATED TO ANGIOGENESIS - A computer-implemented method for determining an optimal treatment protocol for a disease related to angiogenesis, comprising creating an angiogenesis model including pro-angiogenesis and anti-angiogenesis factors. Effective vessel density (EVD) is incorporated as a factor regulating switching on and switching off of at least one component in the angiogenesis model. Effects of vasculature maturation and mature vessels destabilization are incorporated. Pro-angiogenesis and anti-angiogenesis factors, which can influence changes in state of a tissue are selected. Effects of drugs in the pro-angiogenesis and anti-angiogenesis factors are incorporated. A plurality of treatment protocols in a protocol space is generated. A best treatment protocol based on a pre-determined criteria. | 11-06-2008 |
20100161301 | Techniques for Purposing a New Compound and for Re-Purposing a Drug - A method for repurposing a pharmaceutical compound. The method includes identifying a pharmaceutical compound, the pharmaceutical compound corresponding to a drug that has failed in clinical development or an approved drug. A mathematical model describing the physiological processes related to at least one disease and the effects of the pharmaceutical compound on the disease is created. The model is adjusted based upon information from preclinical or clinical trials. A new treatment protocol is suggested to salvage the failed drug or a new way to use an approved drug. The suggested treatment protocol is displayed. Systems and computer program products encompassing the above techniques are also disclosed. | 06-24-2010 |
20100235150 | THERAPEUTIC IMPLICATIONS OF DICKKOPF AFFECTING CANCER STEM CELL FATE - A method of determining a therapeutic regimen for the treatment of cancer with Dickkopf (Dkk) protein in which a mathematical model of differential equations describing the major signaling pathways involved in stem cell regulation is created and used to simulate signals from the cancer stem cell environment based upon administration of at least a single dose of Dkk in vitro and/or in vivo. A method of modulating cancer stem cells is also provided in which the stem cell computer model is simulates the effect of Dkk and performs a calibration test to determine a threshold value above which Dkk induces cell differentiation and a threshold value below which Dkk induces stem cell proliferation. | 09-16-2010 |
20110286960 | CANCER THERAPY BY DOCETAXEL AND GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) - Neutropenia is the dose-limiting toxicity of the tri-weekly docetaxel (Taxotere®) schedule. Here, we evaluate in Metastatic Breast Cancer (MBC) patients (N=38) a computerized method for predicting docetaxel-induced neutropenia, and use the model to identify improved docetaxel and Granulocyte Colony Stimulating Factor (G-CSF) regimens. Pharmacokinetics/pharmacodynamics (PK/PD) models were created and simulated concomitantly with a mathematical granulopoiesis model. Individual baseline neutrophil counts and docetaxel schedules served as inputs. Our trial validated the model accuracy in predicting nadir timings (r=0.99), grade 3/4 neutropenia (86% success) and neutrophil profiles (r=0.62). Model was robust to CYP3A-induced variability, except for slightly less accurate grade 3/4 neutropenia predictions. Simulations confirm smaller toxicity of the weekly docetaxel regimen than the tri-weekly one, and suggest an optimal G-CSF support for alleviating neutropenia, 60 μg/day QD×3, 6-7 days post-docetaxel, administered tri- and bi-weekly, and 4 days post weekly docetaxel>33 mg/m | 11-24-2011 |
20120284005 | SYSTEM AND METHODS FOR OPTIMIZED DRUG DELIVERY AND PROGRESSION OF DISEASED AND NORMAL CELLS - System for recommending an optimal treatment protocol for a specific individual are disclosed. The systems comprise generally a system model, a plurality of treatment protocols, a system model modifier, wherein said system model is modified by the system model modifier based on parameters specific to the individual; and a selector to select an optimal treatment protocol from said plurality of treatment protocols based on the modified system model. Systems embodying the above techniques but for a general patient are also disclosed. Systems for a general patient and an individual for various specific diseases are disclosed. Methods and computer program products embodying the above techniques are also disclosed. | 11-08-2012 |